DDInter364 DDInter474
Chlorpropamide is an oral antihyperglycemic agent used for the treatment of non-insulin-dependent diabetes mellitus (NIDDM). It belongs to the sulfonylurea class of insulin secretagogues, which act by stimulating β cells of the pancreas to release insulin. Sulfonylureas increase both basal insulin secretion and meal-stimulated insulin release. Medications in this class differ in their dose, rate of absorption, duration of action, route of elimination and binding site on their target pancreatic β cell receptor. Sulfonylureas also increase peripheral glucose utilization, decrease hepatic gluconeogenesis and may increase the number and sensitivity of insulin receptors. Sulfonylureas are associated with weight gain, though less so than insulin. Due to their mechanism of action, sulfonylureas may cause hypoglycemia and require consistent food intake to decrease this risk. The risk of hypoglycemia is increased in elderly, deb
Dapagliflozin is a sodium-glucose cotransporter 2 (SGLT2) inhibitor, and it was the first SLGT2 inhibitor to be approved. indicated for managing diabetes mellitus type 2. When combined with diet and exercise in adults, dapagliflozin helps to improve glycemic control by inhibiting glucose reabsorption in the proximal tubule of the nephron and causing glycosuria. Dapagliflozin has been investigated either as monotherapy or as an adjunct treatment with insulin or other oral hypoglycemic agents. Dapagliflozin was originally approved by the FDA on Jan 08, 2014, to improve glycemic control in adults with type 2 diabetes in conjunction with diet and exercise. It was later approved to reduce the risk of kidney function decline, kidney failure, cardiovascular death, and hospitalization for heart failure in adults with chronic kidney disease in April 2021.
Chlorpropamide {u} (Compound) binds {v} (Gene) ABCB1
ABCB1 {u} (Gene) is bound by {v} (Compound) Dapagliflozin
Chlorpropamide {u} (Compound) causes {v} (Side Effect) Hypoglycaemia
Hypoglycaemia {u} (Side Effect) is caused by {v} (Compound) Dapagliflozin
Chlorpropamide {u} (Compound) resembles {v} (Compound) Glipizide
Glipizide {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Dapagliflozin
Chlorpropamide {u} (Compound) resembles {v} (Compound) Tolbutamide
Tolbutamide {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Dapagliflozin
Chlorpropamide {u} (Compound) binds {v} (Gene) ABCB1
ABCB1 {u} (Gene) is bound by {v} (Compound) Canagliflozin
Canagliflozin {u} (Compound) resembles {v} (Compound) Dapagliflozin
Chlorpropamide {u} (Compound) binds {v} (Gene) CYP2C9
CYP2C9 {u} (Gene) is bound by {v} (Compound) Simvastatin
Simvastatin {u} may cause a minor interaction that can limit clinical effects when taken with {v} Dapagliflozin
Chlorpropamide {u} (Compound) causes {v} (Side Effect) Hypoglycaemia
Hypoglycaemia {u} (Side Effect) is caused by {v} (Compound) Canagliflozin
Canagliflozin {u} (Compound) resembles {v} (Compound) Dapagliflozin
Chlorpropamide {u} (Compound) causes {v} (Side Effect) Headache
Headache {u} (Side Effect) is caused by {v} (Compound) Simvastatin
Simvastatin {u} may cause a minor interaction that can limit clinical effects when taken with {v} Dapagliflozin
Chlorpropamide {u} (Compound) causes {v} (Side Effect) Hyponatraemia
Hyponatraemia {u} (Side Effect) is caused by {v} (Compound) Regorafenib
Regorafenib {u} may cause a minor interaction that can limit clinical effects when taken with {v} Dapagliflozin
Chlorpropamide {u} (Compound) resembles {v} (Compound) Glipizide
Glipizide {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Canagliflozin
Canagliflozin {u} (Compound) resembles {v} (Compound) Dapagliflozin
Chlorpropamide (Compound) binds ABCB1 (Gene) and ABCB1 (Gene) is bound by Dapagliflozin (Compound)
Chlorpropamide (Compound) causes Hypoglycaemia (Side Effect) and Hypoglycaemia (Side Effect) is caused by Dapagliflozin (Compound)
Chlorpropamide (Compound) resembles Glipizide (Compound) and Glipizide may cause a moderate interaction that could exacerbate diseases when taken with Dapagliflozin
Chlorpropamide (Compound) resembles Tolbutamide (Compound) and Tolbutamide may cause a moderate interaction that could exacerbate diseases when taken with Dapagliflozin
Chlorpropamide (Compound) binds ABCB1 (Gene) and ABCB1 (Gene) is bound by Canagliflozin (Compound) and Canagliflozin (Compound) resembles Dapagliflozin (Compound)
Chlorpropamide (Compound) binds CYP2C9 (Gene) and CYP2C9 (Gene) is bound by Simvastatin (Compound) and Simvastatin may cause a minor interaction that can limit clinical effects when taken with Dapagliflozin
Chlorpropamide (Compound) causes Hypoglycaemia (Side Effect) and Hypoglycaemia (Side Effect) is caused by Canagliflozin (Compound) and Canagliflozin (Compound) resembles Dapagliflozin (Compound)
Chlorpropamide (Compound) causes Headache (Side Effect) and Headache (Side Effect) is caused by Simvastatin (Compound) and Simvastatin may cause a minor interaction that can limit clinical effects when taken with Dapagliflozin
Chlorpropamide (Compound) causes Hyponatraemia (Side Effect) and Hyponatraemia (Side Effect) is caused by Regorafenib (Compound) and Regorafenib may cause a minor interaction that can limit clinical effects when taken with Dapagliflozin
Chlorpropamide (Compound) resembles Glipizide (Compound) and Glipizide may cause a moderate interaction that could exacerbate diseases when taken with Canagliflozin and Canagliflozin (Compound) resembles Dapagliflozin (Compound)